Abstract:Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45 + cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.

Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy

Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Neutrophils in glioma microenvironment: from immune function to immunotherapy

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

Tumor-associated Neutrophils in Tumor Development and Progression

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

Neutrophils: New Critical Regulators of Glioma

The Evolution of Tumor Microenvironment in Gliomas and Its Implication for Target Therapy

Tumor-associated neutrophils and neutrophil-targeted cancer therapies

Rational targeting of immunosuppressive neutrophils in cancer

Roles of Neutrophils in Glioma and Brain Metastases

Tumor Microenvironment‐Enabled Nanotherapy

Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Interactions between microglia and glioma in tumor microenvironment

Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment

Immune response in glioma’s microenvironment

Regulation of tumor immunity by metabolism of glioma cells and immune cells in tumor microenvironment

Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis

TAMI-38. TUMOR-ASSOCIATED NEUTROPHILS IN GLIOBLASTOMA PROMOTE THE PERIVASCULAR GLIOMA STEM-LIKE CELL NICHE VIA OSTEOPONTIN SECRETION

Tumor-specific Neutrophils Originating from Meninges Promote Glioblastoma